Published
6 mins ago
on
October 21, 2024
| 12 views
-->
By
Jenna Ross
Graphics & Design
- Jennifer West
- Alejandra Dander
The following content is sponsored by the MSCI Sustainability Institute
Charted: Deaths Related to Bacterial Infection vs. Research Efforts
More people die every year directly from antimicrobial resistance than from HIV/AIDS, malaria, or any one form of cancer other than lung cancer. Clearly, a drug-resistant bacterial infection is a major health threat. But are researchers giving infections the attention they need?
In part two of this series on antimicrobial resistance, we partnered with the MSCI Sustainability Institute to show the gap between deaths related to bacterial infection and research efforts.
The Mismatch Between Deaths and Research
Globally, a bacterial infection causes nearly 14% of deaths. More than half of these deaths are linked to resistance. Unfortunately, fewer than 2% of all clinical trials study bacterial infections.
With rising antibiotic resistance, new drugs are desperately needed—but research isn’t keeping up. There are far more products in development for cancer, neuropsychiatric conditions, and other non-communicable diseases.
Even among the antibiotics that researchers are developing, the World Health Organization found that they had little benefit over existing drugs and very few target the most resistant bacteria.
The Challenges of Tackling Bacterial Infection
Why are companies developing so few drugs? Manufacturers face challenges and a lack of financial incentives:
- Small companies account for 81% of antibacterial therapeutics in clinical testing, but have difficulty securing stable funding throughout product development.
- New antimicrobials are managed carefully and used as a last resort, making high-volume sales unrealistic.
- Compared to many other drugs, antibiotics are used for a shorter period of time and have a limited lifespan due to rising resistance.
The lack of investment into new treatments is a serious problem, but also presents an opportunity.
Opportunities for Investors
Governments can play a role in addressing these issues. One example is the UK’s “subscription-style” model for antibiotics which pays companies upfront to access their drug based on its value rather than the amount used.
There’s also substantial room for investors to create change. For instance, investors can engage with companies on antimicrobial resistance issues, such as a meat producer’s antibiotic use. They can also help fund research across the product development cycle to speed up new drugs or alternative treatments.
Related Topics: #research #death #clinical trials #msci #MSCI Sustainability Institute #infection #bacterial infection #antibiotics #antimicrobials
Click for Comments
var disqus_shortname = "visualcapitalist.disqus.com";
var disqus_title = "Charted: Deaths Related to Bacterial Infection vs. Research Efforts";
var disqus_url = "https://www.visualcapitalist.com/sp/msci05-deaths-bacterial-infection-vs-research-efforts/";
var disqus_identifier = "visualcapitalist.disqus.com-171242";
You may also like
-
Healthcare2 days ago
Ranked: The Top 20 Causes of Death in 2021
Globally, over 68 million people died in 2021. This graphic uses the latest available data to show the leading causes of death worldwide.
-
Healthcare3 weeks ago
Which Countries Are the Healthiest in 2024?
The world’s two healthiest countries are home to ‘blue zones’, where the centenarian population is 10 times higher per capita than America.
-
Healthcare1 month ago
Ranked: Women’s Life Expectancy in Developed Nations
See the latest data on women’s life expectancy across a group of high-income countries. Can you guess where the U.S. ranks?
-
United States2 months ago
Mapped: U.S. Obesity Rates, by State
Three U.S. states recorded an adult obesity rate of 40% or higher in 2022. Which states saw the highest obesity rates?
-
Maps3 months ago
Mapped: Countries With the Highest Adult Obesity Rates
The U.S. ranks 15th in the highest adult obesity rates. Qatar and Egypt are the only other 1 million+ countries to feature.
-
Healthcare3 months ago
Charted: Life Expectancy vs. Health Spending Per Capita
America’s per capita health spend is now past $12,500, but for what gains? A quick comparison with its peers.
Subscribe
Please enable JavaScript in your browser to complete this form.Join the 375,000+ subscribers who receive our daily email *Sign Up
The post Charted: Deaths Related to Bacterial Infection vs. Research Efforts appeared first on Visual Capitalist.